1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Sartorius AG

Sartorius AG

SOAGY
Sartorius AGUS flagOther OTC
56.49
USD
-0.36
- -
82.54BMarket Cap
Sartorius AG
SOAGY
(Other OTC)

Recent

price

56.97

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.93
2.15
2.48
2.32
2.61
3.27
3.8
4.11
4.58
5.34
6.83
10.08
12.2
9.93
9.8
10.25
7.83
Revenue per Share
0.12
0.12
0.14
0.15
0.14
0.37
0.3
0.34
0.41
0.46
0.61
0.93
1.98
0.6
0.24
0.45
0.53
Basic EPS, GAAP
0.21
0.08
-0.03
0.3
0.38
0.37
0.5
0.6
0.72
1.1
1.5
2.55
2.15
0.86
1.64
1.14
1.05
Free Cash Flow per Basic Share
0.03
0.03
0.04
0.05
0.05
0.07
0.08
0.09
0.1
0.12
0.07
0.14
0.25
0.29
0.15
0.15
0.15
Dividend per Share
0.56
0.64
0.05
0.05
0.05
0.05
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
Book Value per Share
-0.22
-0.28
-0.32
-0.29
-0.16
0.09
- -
-0.8
-0.26
-0.1
-2.46
-2.16
-1
-8.03
-4.56
-4.14
-4.04
Tangible Book Value per Share
341
341
341
341
341
341
342
342
342
342
342
342
342
342
345
345
346
Basic Weighted Avg Shares
659
733
846
792
891
1,115
1,300
1,405
1,566
1,827
2,336
3,449
4,175
3,396
3,381
3,538
2,711
Sales/Revenue/Turnover
10.93
14.51
14.53
14.65
14.6
18.99
19.05
18.72
19.2
19.89
21.89
27.06
27.29
16.02
12.93
16.09
16.82
Operating Margin (%)
32
33
41
48
55
59
76
98
113
133
180
231
287
342
416
420
320
Depreciation Expense
41
42
49
52
48
126
103
115
141
157
210
319
678
206
84
155
182
Net Income, GAAP
35.13
33.21
31.59
30.71
33.65
31.9
28.96
20.81
27.05
27.85
29.47
36.12
22.73
24.85
26.45
31.6
32.89
Effective Tax Rate (%)
6.17
5.67
5.74
6.62
5.44
11.33
7.92
8.17
9.03
8.58
9
9.25
16.24
6.05
2.48
4.38
6.71
Profit Margin (%)
40
48
34
146
187
206
223
278
273
188
338
250
220
627
669
-201
-190
Working Capital
207
271
247
369
379
366
452
887
895
881
1,892
1,738
1,986
5,023
4,167
3,356
3,337
LT Debt
327
366
404
450
498
645
737
807
973
1,093
1,380
1,720
2,659
2,758
3,898
3,867
3,891
Total Equity
7.87
11.15
11.43
9.79
9.67
14.47
14.64
13.26
11.37
12.23
12.36
15.65
18.53
5.93
3.79
4.59
3.63
Return on Invested Capital (%)
11.56
7.31
8.1
9.1
7.47
19.27
10.29
8.23
7.61
7.8
6.95
8.93
15.99
4.91
2.81
3.52
4.58
Return on Capital (%)
21.65
20.27
40.95
307.53
284.47
739.83
240.82
167.76
206.68
229.12
307.15
466.17
991.37
300.58
122.27
224.33
263.43
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
926
964
LT Borrowings
- -
3,184
3,169
LT Finance Leases
- -
172
168
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
69
69
69
Market Capitalization
13,763
17,113
14,884

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
1,766
1,923
Cash, Cash Equivalents & STI
- -
552
600
Accounts Receivable, Net
- -
225
304
Inventories
- -
792
827
Total Current Liabilities
- -
1,967
2,113
Payables & Accruals
- -
- -
- -
ST Debt
- -
926
964
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.65%
24.7%
-0.78%
Free Cash Flow
22.27%
11.45%
-30.23%
Net Income, GAAP
18.11%
24%
84.4%
Sales/Revenue/Turnover
13.49%
10.85%
4.66%
Total Cash Common Dividend
16.23%
28.58%
0.2%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
820
861
794
907
3,381
2025
883
884
- -
928
3,538
2026
899
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.07
0.02
- -
0.24
2025
0.14
0.09
- -
- -
0.45
2026
0.16
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.15
2025
- -
- -
- -
- -
0.15
2026
0.15
- -
- -
- -
- -
Similar Companies
Formosa Optical Technology Co.,Ltd. (5312.TWO)
Modern Dental Group Limited (3600.HK)
Medikit Co.,Ltd. (7749.T)
NEXGEL, Inc. (NXGLW)
Cardiac Biotech Solutions Inc. (CBSC)
Innovative Eyewear, Inc. (LUCYW)
Business
Sartorius AG (SOAGY) is a leading international partner for biopharmaceutical research and the industry, providing innovative laboratory and process technology solutions. The company offers a broad portfolio of products and services including laboratory balances and pipettes under the Sartorius brand; filtration and purification systems such as Sartopore filters and Sartobind membranes; single-use bioreactor systems like the Biostat STR; bioprocess containers and assemblies; cell line development tools including ambr mini bioreactors; and process analytical technology solutions like Octet SPR systems; as well as services for bioprocess development, validation, and scale-up support. Sartorius operates in two main divisions: Sartorius Bioprocess Solutions, which focuses on tools for upstream and downstream bioprocessing, and Sartorius Lab Instruments and Services, serving research and quality control labs. The company serves biopharmaceutical manufacturers, research institutions, and industrial labs worldwide, with manufacturing sites and sales offices across Europe, North America, Asia-Pacific, and Latin America; it was founded in 1870 and is headquartered in Göttingen, Germany. In recent developments, Sartorius AG completed the acquisition of Danaher's Cytiva business in 2023, significantly expanding its bioprocess portfolio with complementary technologies in chromatography and filtration. The company launched the Sartorius Sartobrew tubes in 2024 for large-scale microbial fermentation and introduced the iQue advanced flow cytometry platform following the 2023 acquisition of IntelliCyt. Additionally, Sartorius formed strategic partnerships, including a collaboration with Roche in 2025 for process intensification in antibody production, and announced expansions in single-use bag production capacity in Germany and Singapore to meet growing demand in cell and gene therapy markets. These moves underscore Sartorius' focus on accelerating bioprocessing innovation amid rising global demand for biologics and personalized medicines.

Company News

APIChat

  • defenseworld.net

    Sartorius Aktiengesellschaft (OTCMKTS:SOAGY) Short Interest Update

  • seekingalpha.com

    Sartorius Aktiengesellschaft (SOAGY) Q3 2025 Earnings Call Transcript